Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease
Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis. This consensus on 5-ASA is obtained through a modified Delphi process, and includes guiding statements and recommendations ba...
Main Authors: | Ajit Sood, Vineet Ahuja, Vandana Midha, Saroj Kant Sinha, C. Ganesh Pai, Saurabh Kedia, Varun Mehta, Sawan Bopanna, Philip Abraham, Rupa Banerjee, Shobna Bhatia, Karmabir Chakravartty, Sunil Dadhich, Devendra Desai, Manisha Dwivedi, Bhabhadev Goswami, Kirandeep Kaur, Rajeev Khosla, Ajay Kumar, Ramit Mahajan, S. P. Misra, Kiran Peddi, Shivaram Prasad Singh, Arshdeep Singh |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Association for the Study of Intestinal Diseases
2020-10-01
|
Series: | Intestinal Research |
Subjects: | |
Online Access: | http://www.irjournal.org/upload/pdf/ir-2019-09176.pdf |
Similar Items
-
The culprit of mesalamine intolerance: case series and literature review
by: Cheng Xie, et al.
Published: (2019-07-01) -
Preparation and evaluation of magnetic microspheres of mesalamine (5-aminosalicylic acid) for colon drug delivery
by: Satinder Kakar, et al.
Published: (2013-01-01) -
Aminosalicylates in inflammatory bowel disease
by: Vojislav N. Perisic
Published: (2013-10-01) -
Nephrotic syndrome after treatment of Crohn′s disease with mesalamine: Case report and literature review
by: Belal M Firwana, et al.
Published: (2012-01-01) -
Higher education, professional occupation, and upper socioeconomic status are associated with lower adherence to medications in patients with inflammatory bowel disease
by: Sanjeevani K Tomar, et al.
Published: (2019-08-01)